{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:06:39Z","timestamp":1784804799472,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T00:00:00Z","timestamp":1466121600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1208\/s12248-016-9941-y","type":"journal-article","created":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T13:45:57Z","timestamp":1466171157000},"page":"1254-1261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Urinary 6\u03b2-Hydroxycortisol\/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach"],"prefix":"10.1208","volume":"18","author":[{"given":"Kwang-Hee","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Young","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man Ho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Yeon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Youn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,17]]},"reference":[{"issue":"5","key":"9941_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/clpt.2013.166","volume":"94","author":"LP James","year":"2013","unstructured":"James LP. Metabolomics: integration of a new \u201comics\u201d with clinical pharmacology. Clin Pharmacol Ther. 2013;94(5):547\u201351. doi: 10.1038\/clpt.2013.166 .","journal-title":"Clin Pharmacol Ther"},{"issue":"34","key":"9941_CR2","doi-asserted-by":"publisher","first-page":"14728","DOI":"10.1073\/pnas.0904489106","volume":"106","author":"TA Clayton","year":"2009","unstructured":"Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A. 2009;106(34):14728\u201333. doi: 10.1073\/pnas.0904489106 .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7087","key":"9941_CR3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nature04648","volume":"440","author":"TA Clayton","year":"2006","unstructured":"Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006;440(7087):1073\u20137. doi: 10.1038\/nature04648 .","journal-title":"Nature"},{"issue":"2","key":"9941_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.103.054841","volume":"307","author":"JC Stevens","year":"2003","unstructured":"Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther. 2003;307(2):573\u201382. doi: 10.1124\/jpet.103.054841 .","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"9941_CR5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1124\/dmd.30.8.883","volume":"30","author":"JA Williams","year":"2002","unstructured":"Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos Biol Fate Chem. 2002;30(8):883\u201391.","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"8","key":"9941_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1358\/mf.2005.27.8.928310","volume":"27","author":"DR Krishna","year":"2005","unstructured":"Krishna DR, Shekar MS. Cytochrome P450 3A: genetic polymorphisms and inter-ethnic differences. Methods Find Exp Clin Pharmacol. 2005;27(8):559\u201367. doi: 10.1358\/mf.2005.27.8.928310 .","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"2","key":"9941_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/tpj.2010.16","volume":"11","author":"E Gebeyehu","year":"2011","unstructured":"Gebeyehu E, Engidawork E, Bijnsdorp A, Aminy A, Diczfalusy U, Aklillu E. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenomics J. 2011;11(2):130\u20137. doi: 10.1038\/tpj.2010.16 .","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"9941_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00003088-200544010-00002","volume":"44","author":"MM Cotreau","year":"2005","unstructured":"Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinetics. 2005;44(1):33\u201360. doi: 10.2165\/00003088-200544010-00002 .","journal-title":"Clin Pharmacokinetics"},{"issue":"5","key":"9941_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.clpt.2006.08.014","volume":"80","author":"M Chen","year":"2006","unstructured":"Chen M, Ma L, Drusano GL, Bertino Jr JS, Nafziger AN. Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther. 2006;80(5):531\u20138. doi: 10.1016\/j.clpt.2006.08.014 .","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"9941_CR10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","volume":"54","author":"JK Lamba","year":"2002","unstructured":"Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Delivery Rev. 2002;54(10):1271\u201394.","journal-title":"Adv Drug Delivery Rev"},{"issue":"5","key":"9941_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/clpt.2013.128","volume":"94","author":"KH Shin","year":"2013","unstructured":"Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ, Cho JY. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin Pharmacol Ther. 2013;94(5):601\u20139. doi: 10.1038\/clpt.2013.128 .","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9941_CR12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00000542-199707000-00005","volume":"87","author":"ED Kharasch","year":"1997","unstructured":"Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology. 1997;87(1):26\u201335.","journal-title":"Anesthesiology"},{"issue":"9","key":"9941_CR13","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.jasms.2009.04.020","volume":"20","author":"JY Moon","year":"2009","unstructured":"Moon JY, Jung HJ, Moon MH, Chung BC, Choi MH. Heat-map visualization of gas chromatography\u2013mass spectrometry based quantitative signatures on steroid metabolism. J Am Soc Mass Spectrom. 2009;20(9):1626\u201337. doi: 10.1016\/j.jasms.2009.04.020 .","journal-title":"J Am Soc Mass Spectrom"},{"issue":"32","key":"9941_CR14","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1016\/j.jchromb.2009.11.010","volume":"877","author":"YW Ha","year":"2009","unstructured":"Ha YW, Moon JY, Jung HJ, Chung BC, Choi MH. Evaluation of plasma enzyme activities using gas chromatography\u2013mass spectrometry based steroid signatures. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(32):4125\u201332. doi: 10.1016\/j.jchromb.2009.11.010 .","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"4","key":"9941_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/FTD.0b013e318286ee02","volume":"35","author":"JY Moon","year":"2013","unstructured":"Moon JY, Kang SM, Lee J, Cho JY, Moon MH, Jang IJ, et al. GC-MS-based quantitative signatures of cytochrome P450-mediated steroid oxidation induced by rifampicin. Ther Drug Monit. 2013;35(4):473\u201384. doi: 10.1097\/FTD.0b013e318286ee02 .","journal-title":"Ther Drug Monit"},{"issue":"8","key":"9941_CR16","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1124\/dmd.113.052316","volume":"41","author":"L Bjorkhem-Bergman","year":"2013","unstructured":"Bjorkhem-Bergman L, Backstrom T, Nylen H, Ronquist-Nii Y, Bredberg E, Andersson TB, et al. Comparison of endogenous 4beta-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Dispos. 2013;41(8):1488\u201393. doi: 10.1124\/dmd.113.052316 .","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"9941_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00228-003-0690-3","volume":"59","author":"MM Galteau","year":"2003","unstructured":"Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol. 2003;59(10):713\u201333. doi: 10.1007\/s00228-003-0690-3 .","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"9941_CR18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/clpt.2011.53","volume":"89","author":"CC Peng","year":"2011","unstructured":"Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, Isoherranen N. Evaluation of 6beta-hydroxycortisol, 6beta-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin Pharmacol Ther. 2011;89(6):888\u201395. doi: 10.1038\/clpt.2011.53 .","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"9941_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/clpt.2012.145","volume":"92","author":"MF Fromm","year":"2012","unstructured":"Fromm MF. Prediction of transporter-mediated drug-drug interactions using endogenous compounds. Clin Pharmacol Ther. 2012;92(5):546\u20138. doi: 10.1038\/clpt.2012.145 .","journal-title":"Clin Pharmacol Ther"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-016-9941-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-016-9941-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-016-9941-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T12:35:53Z","timestamp":1498307753000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-016-9941-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,17]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["9941"],"URL":"https:\/\/doi.org\/10.1208\/s12248-016-9941-y","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,17]]}}}